<DOC>
	<DOCNO>NCT02415881</DOCNO>
	<brief_summary>Phase I trial evaluate safety escalate dose level conjugate panitumumab-IRDye800 subject head neck squamous cell carcinoma ( HNSCC ) undergo surgery curative intent .</brief_summary>
	<brief_title>Phase I Panitumumab IRDye800 Optical Imaging Study</brief_title>
	<detailed_description>This Phase I trial design evaluate safety escalate dose level conjugate panitumumab-IRDye800 use subject head neck squamous cell carcinoma ( HNSCC ) undergo surgery curative intent . Safety data trial studied assist selection dose level panitumumab-IRDye800 future research . It hop study also help find good method identify cancer intraoperatively complete surgical resection .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria Biopsy confirm diagnosis squamous cell carcinoma head neck Patients diagnose T stage , subsite within head neck schedule undergo surgical resection . Patients recurrent disease new primary allow . Planned standard care surgery curative intent squamous cell carcinoma Age ≥ 19 year Have life expectancy 12 week Karnofsky performance status least 70 % ECOG/Zubrod level 1 Have acceptable hematologic status , coagulation status , kidney function , liver function include follow clinical result : Hemoglobin ≥ 9 gm/dL ; White blood cell count &gt; 3000/mm3 ; Platelet count ≥ 100,000/mm3 ; Serum creatinine ≤ 1.5 time upper reference range Exclusion Criteria Received investigational drug within 30 day prior first dose panitumumab IRDye800 Myocardial infarction ( MI ) ; cerebrovascular accident ( CVA ) ; uncontrolled congestive heart failure ( CHF ) ; significant liver disease ; unstable angina within 6 month prior enrollment History infusion reaction monoclonal antibody therapy Pregnant breastfeed Evidence QT prolongation pretreatment ECG ( great 440 m male great 450 m female ) Magnesium potassium lower normal institutional value Patients receive Class IA ( quinidine , procanamide ) Class III ( dofetilide , amiodarone , sotalol ) antiarrhythmic agent . Patients history evidence interstitial pneumonitis pulmonary fibrosis TSH &gt; 13 micro International Units/mL</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Panitumumab</keyword>
	<keyword>Optical Imaging</keyword>
</DOC>